Hoth Therapeutics Expands HT-001 Development with Patent Filings Targeting Drug-Induced Hypersensitivity, Radiotherapy-Induced Rash, and MENIN Inhibitor-Associated Skin Toxicities
Hoth Therapeutics (NASDAQ: HOTH) has expanded its intellectual property portfolio for HT-001, its lead topical therapeutic candidate, by filing multiple U.S. Provisional Patent Applications. The patents cover three new indications: drug-induced hypersensitivity syndrome, radiotherapy-induced rash, and dermatological conditions associated with MENIN inhibitor therapy.
The expansion particularly focuses on addressing skin toxicities associated with MENIN inhibitors, an emerging class of targeted oncology drugs showing promise in treating acute leukemias and solid tumors. HT-001's novel topical formulation aims to help patients manage treatment-related skin conditions without interrupting their cancer therapy, potentially enabling longer treatment duration and better clinical outcomes.
Hoth Therapeutics (NASDAQ: HOTH) ha ampliato il proprio portafoglio di proprietà intellettuale per HT-001, il candidato topico principale, depositando diverse domande di brevetto provvisorie negli Stati Uniti. I brevetti coprono tre nuove indicazioni: sindrome da ipersensibilità causata da farmaci, esantema da radioterapia e condizioni dermatologiche associate alla terapia con inibitori di MENIN
L’espansione si concentra in particolare sull’affrontare le tossicità cutanee legate agli inibitori di MENIN, una classe emergente di farmaci oncologici mirati che mostrano potenzialità nel trattamento di leucemie acute e tumori solidi. La nuova formulazione topica di HT-001 mira ad aiutare i pazienti a gestire le condizioni della pelle legate al trattamento senza interrompere la terapia oncologica, potenzialmente consentendo una durata del trattamento più lunga e migliori esiti clinici.
Hoth Therapeutics (NASDAQ: HOTH) ha ampliado su cartera de propiedad intelectual para HT-001, su principal candidato terapéutico tópico, al presentar varias solicitudes de patentes provisionales en EE. UU. Las patentes abarcan tres nuevas indicaciones: síndrome de hipersensibilidad inducida por fármacos, erupción inducida por radioterapia y condiciones dermatológicas asociadas con la terapia con inhibidores de MENIN.
La expansión se centra especialmente en abordar las toxicidades cutáneas asociadas con los inhibidores de MENIN, una clase emergente de fármacos oncológicos dirigidos que muestran potencial para tratar leucemias agudas y tumores sólidos. La innovadora formulación tópica de HT-001 tiene como objetivo ayudar a los pacientes a manejar las condiciones de la piel relacionadas con el tratamiento sin interrumpir la terapia contra el cáncer, lo que podría permitir una mayor duración del tratamiento y mejores resultados clínicos.
Hoth Therapeutics (NASDAQ: HOTH)는 HT-001, 선도적인 국소 치료 후보물질의 지적 재산 포트폴리오를 확장하여 미국에서 다수의 예비 특허 출원을 제출했습니다. 특허는 세 가지 새로운 적응증을 다룹니다: 약물 유발 과민증 증후군, 방사선 치료로 인한 발진, 및 MENIN 억제제 치료와 관련된 피부 질환입니다.
이 확장은 특히 MENIN 억제제와 관련된 피부 독성 문제를 다루는 데 중점을 두고 있으며, 표적 암 치료제의 신흥 계열로서 급성 백혈병과 고형암 치료에 가능성을 보이고 있습니다. HT-001의 새로운 국소 제형은 치료로 인한 피부 질환을 암 치료를 중단하지 않고 관리하도록 돕는 것을 목표로 하며, 더 긴 치료 기간과 더 나은 임상 결과를 가능하게 할 수 있습니다.
Hoth Therapeutics (NYSE: HOTH) a élargi son portefeuille de propriété intellectuelle pour HT-001, son candidat thérapeutique topique phare, en déposant plusieurs demandes de brevets provisoires aux États-Unis. Les brevets couvrent trois nouvelles indications : syndrome d’hypersensibilité médicamenteuse, éruption cutanée induite par la radiothérapie et des conditions dermatologiques associées à la thérapie par inhibiteurs de MENIN
Cette expansion met particulièrement l’accent sur le traitement des toxicités cutanées associées aux inhibiteurs de MENIN, une classe émergente de médicaments oncologiques ciblés qui montre des promesses dans le traitement des leucémies aiguës et des tumeurs solides. La formulation topique novatrice de HT-001 vise à aider les patients à gérer ces affections cutanées liées au traitement sans interrompre la thérapie anticancéreuse, ce qui pourrait permettre une durée de traitement plus longue et de meilleurs résultats cliniques.
Hoth Therapeutics (NASDAQ: HOTH) hat sein Portfolio an geistigem Eigentum für HT-001, seinen führenden topischen Kandidaten, durch die Einreichung mehrerer US-Provisorischer Patentanmeldungen erweitert. Die Patente decken drei neue Indikationen ab: medikamenteninduzierte Hypersensitivitäts-Syndrom, durch Strahlentherapie verursachte Hautausschläge und dermatologische Erkrankungen im Zusammenhang mit der MENIN-Inhibitor-Therapie.
Die Erweiterung konzentriert sich insbesondere darauf, Hauttoxizitäten im Zusammenhang mit MENIN-Inhibitoren anzugehen, einer aufkommenden Klasse gezielter Krebstherapeutika, die vielversprechende Ergebnisse bei akuter Leukämie und soliden Tumoren zeigen. HT-001s neuartige topische Formulierung zielt darauf ab, Patienten zu helfen, behandlungsbedingte Hautzustände zu bewältigen, ohne die Krebsbehandlung zu unterbrechen, was potenziell eine längere Therapiedauer und bessere klinische Ergebnisse ermöglicht.
Hoth Therapeutics (بورصة ناسداك: HOTH) قد وسّعت محفظة الملكية الفكرية الخاصة بها لـ HT-001، مرشحها العلاجي الموضعي الرائد، من خلال تقديم عدة طلبات براءة اختراع أولية في الولايات المتحدة. تغطي براءات الاختراع ثلاث مؤشرات جديدة: متلازمة فرط الحساسية الدوائية، الطفح الجلدي الناتج عن العلاج الإشعاعي، والحالات الجلدية المرتبطة بعلاج مثبطات MENIN.
تركّز التوسعة بشكل خاص على معالجة السميّات الجلدية المرتبطة بمثبِّطات MENIN، وهي فئة متنامية من أدوية الأورام المستهدفة التي تبدي وعداً في علاج سرطانات الدم الحاد والورمَيات الصلبة. تُعِدّ صيغة HT-001(topical) المبتكرة لمساعدة المرضى في إدارة حالات الجلد المصاحبة للعلاج دون انقطاع العلاج من السرطان، مما قد يسمح بمدة علاج أطول ونتائج سريرية أفضل.
Hoth Therapeutics（纳斯达克股票代码：HOTH） 通过在美国提交多项临时专利申请，扩展了其针对主打外用药物 HT-001 的知识产权组合。专利覆盖三项新适应症：药物诱发的过敏综合征、放疗引起的皮疹以及与 MENIN 抑制剂治疗相关的皮肤病状。
此次扩展特别聚焦于解决与 MENIN 抑制剂相关的皮肤毒性，这是一个新兴的靶向肿瘤药物领域，在治疗急性白血病和实体瘤方面显示出潜力。HT-001 的新型外用制剂旨在帮助患者管理治疗相关的皮肤状况，而不中断抗癌治疗，从而可能实现更长的治疗周期和更好的临床结果。
- Expansion of IP portfolio with multiple new patent applications
- Broadened commercial potential by targeting additional high-value indications
- Strategic positioning in the growing MENIN inhibitor therapy market
- Potential to improve patient adherence to cancer treatments by managing side effects
- Early-stage development with no efficacy data presented
- No timeline provided for clinical development in new indications
Insights
Hoth's strategic patent filings expand HT-001's commercial potential in addressing treatment-limiting skin toxicities for cancer therapies.
Hoth Therapeutics' latest provisional patent filings represent a significant strategic expansion of their intellectual property portfolio for HT-001, their lead topical therapeutic. The company is positioning HT-001 beyond its initial focus on chemotherapy-induced rash to address three additional high-value indications: drug-induced hypersensitivity syndrome, radiotherapy-induced rash, and MENIN inhibitor-associated skin toxicities.
The most noteworthy aspect of these filings is the targeting of MENIN inhibitor therapy side effects. MENIN inhibitors represent an emerging class of oncology drugs showing promise in acute leukemias and select solid tumors. However, their clinical utility is currently limited by severe dermatological side effects that often force dose reductions or treatment discontinuation. By developing a topical therapy that could mitigate these side effects, Hoth is addressing a significant clinical challenge that could unlock the full therapeutic potential of this drug class.
From an intellectual property perspective, these provisional applications create a strategic advantage by staking an early claim in treating dermatological toxicities associated with newer cancer therapies. This approach allows Hoth to potentially secure market exclusivity in what could become a valuable niche in oncology supportive care. The company is effectively building a broader platform around HT-001 rather than pursuing a single indication strategy, which enhances both the commercial potential and partnership opportunities.
These patent filings follow the standard biotechnology development playbook of expanding potential market applications while the core technology progresses through clinical development. This parallel approach to clinical and intellectual property development maximizes the potential return on R&D investment while creating multiple paths to commercial success.
MENIN inhibitors are a promising class of targeted oncology drugs in development for acute leukemias and certain solid tumors, but their use is often limited by severe dermatological side effects. HT-001 aims to address these toxicities, helping patients remain on therapy and realize the full benefit of treatment.
Key Highlights
- U.S. Provisional Patents filed expanding HT-001's therapeutic reach.
- Indications covered:
- Drug-Induced Hypersensitivity Syndrome
- Radiotherapy-Induced Rash
- Dermatological Conditions Associated with MENIN Inhibitor Therapy
- MENIN inhibitors are an emerging oncology class with significant promise in acute leukemias and select solid tumors, but treatment-limiting rashes remain a major clinical challenge.
- HT-001 designed to improve tolerability of cancer therapies by addressing dermatological side effects, potentially enabling patients to remain on therapy longer.
The filings include:
- Treatment of Drug-Induced Hypersensitivity Syndrome
- Treatment of Radiotherapy-Induced Rash
- Treatment of Dermatological Conditions Associated with MENIN Inhibitor Therapy
"These additional patent applications demonstrate our commitment to unlocking the full therapeutic potential of HT-001 across multiple high-value indications," said Robb Knie, Chief Executive Officer of Hoth Therapeutics. "Drug-induced hypersensitivity, radiotherapy-related rash, and MENIN inhibitor-associated dermatological conditions represent areas of significant unmet need. Expanding our IP protection into these indications strategically positions Hoth to address major markets in oncology supportive care and beyond."
MENIN Inhibitor Therapy and the Role of HT-001
MENIN inhibitors are an emerging class of targeted oncology drugs designed to block the interaction between the menin protein and MLL1/KMT2A fusion proteins — genetic drivers implicated in acute leukemias and other cancers. Early clinical data from leading oncology companies have shown that MENIN inhibitors can induce strong antitumor activity, making them one of the most closely watched new therapeutic classes in cancer drug development.
However, patients receiving MENIN inhibitors frequently experience significant dermatological side effects, including painful or disfiguring rashes that can lead to dose reductions or treatment discontinuation. These adverse events may limit the full therapeutic potential of MENIN inhibitor therapy.
HT-001's novel topical formulation is designed to address these dermatological toxicities directly, offering patients relief from rash and skin irritation without interrupting or reducing their cancer treatment. By improving tolerability, HT-001 could help patients stay on therapy longer and maximize the clinical benefit of MENIN inhibitors.
Expanding the Potential of HT-001
HT-001 is currently being advanced as a topical therapeutic for chemotherapy-induced rash, a dose-limiting side effect affecting patients receiving EGFR inhibitors and other targeted therapies. The patent filings broaden the potential utility of HT-001 to additional drug-induced and treatment-related skin disorders, further establishing the program as a versatile platform candidate.
"With this expanded IP portfolio, HT-001 is positioned not only as a targeted solution for oncology-related rash but also as a potential cornerstone therapy for a range of dermatological conditions driven by emerging cancer treatments," added Knie. "This expansion underscores our strategy to build durable value through innovation, intellectual property, and pipeline diversification."
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/ .
Forward-Looking Statement
This press release includes forward-looking statements based upon Hoth's current expectations, which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties, and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, and the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems, or the global economy as a whole; our intellectual property; our reliance on third-party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, and timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans, and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms, or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section titled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance, or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events, or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.
Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
View original content to download multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-expands-ht-001-development-with-patent-filings-targeting-drug-induced-hypersensitivity-radiotherapy-induced-rash-and-menin-inhibitor-associated-skin-toxicities-302565370.html
SOURCE Hoth Therapeutics, Inc.
FAQ
What are the new patent applications filed by Hoth Therapeutics (NASDAQ: HOTH) for HT-001?
How does HT-001 benefit cancer patients receiving MENIN inhibitor therapy?
What is the current development status of Hoth Therapeutics' HT-001?
What market opportunity is Hoth Therapeutics targeting with HT-001?
Why are MENIN inhibitors significant for cancer treatment?
